Outlook Therapeutics, Inc.
OTLK$17M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaISELIN23 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
OTLK News
Catalyst Timeline
0 upcoming, 2 past
No catalysts found.
Drug Pipeline
bevacizumab
Age-related Macular Degeneration
ranibizumab
Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
bevacizumab | Phase 3 | Age-related Macular Degeneration | - | |
ranibizumab | Phase 3 | Age-related Macular Degeneration | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply